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Cushing’s syndrome or hypercortisolism is an endocrinological disorder in dogs and occurs with a high incidence. In most of the cases (80-85%), hypercortisolism is caused by hypersecretion of adrenocorticotropic hormone (ACTH) by a corticotroph adenoma of the pituitary gland. This is called ACTH- or pituitary-dependent hypercortisolism (PDH). The remaining cases are ACTH-independent. They are caused by excessive secretion of glucocorticoids by an adrenocortical tumor (AT) that is benign or malignant [Galac et al. 2010]. 
In the research that has been done the last years, it became clear that there are several signalling pathways that are important in the pathogenesis of ATs. This project will focus on the growth hormone-insulin-like growth factor pathway.

Growth hormone (GH) is produced in the anterior lobe of the pituitary gland, but also in extrapituitary sites where it acts on the autocrine and paracrine level. GH mediates its effect through binding with the growth hormone receptor (GHR). It has a direct effect on somatic growth regulation, mostly by stimulating the hepatic insulin-like growth factor I (IGF-I) secretion [Perry et al. 2006].
One of the extra-pituitary sites where GH is produced is canine mammary tissue. The GH production occurs in normal, hyperplastic and neoplastic mammary tissue. The production is stimulated by progestins and it could be mediating the progestin-stimulated development of mammary tumors in dogs [Mol et al. 1995]. 
In human ATs and normal adrenal glands high concentrations of the progesterone receptor (PR) have been demonstrated [De Cremoux et al. 2008]. So it could be possible that progestins also in the adrenal gland stimulate GH production which in turn could stimulate cell-proliferation and hyperplasia. 

The insulin-like growth factor (IGF) system plays a central role in the mechanism of transformation and tumourigenesis [Weber et al. 2000]. The two structurally related polypeptide ligands, IGF-I and insulin-like growth factor II (IGF-II), their receptors and binding proteins are synthesized en secreted by the adrenal glands of various species, but the situation in dogs is not known yet [Fottner et al. 2004]. 
IGF-I and IGF-II act at the endocrine and para/autocrine level with multiple activities [Boulle et al. 1998, Fottner et al. 1998]. Their main growth- and differentiation-promoting effects are mediated through binding to the IGF-I receptor (IGF-IR). The IGF-II receptor (IGF-IIR) only binds IGF-II. It has been implicated as a tumor suppressor gene because the clearance and inactivation of IGF-II is mediated by IGF-IIR [Fottner et al. 2004]. 
The last decade various studies that used transcriptome analysis to study the gene profile expression of human ATs have been performed [Fottner et al. 2004]. Among all studied genes, the IGF-II turned out to be the most overexpressed gene in adrenocortical carcinomas (ACC), in comparison with adrenocortical adenomas (ACA) and is judged as pathognomonic for ACCs [Ragazzon et al. 2011]. 
Based on the studies in ATs in men, the influence of IGF-I on the adrenocortical tumorigenesis is little. In none of the studies the overexpression of IGF-I in ATs could be demonstrated [Fottner et al. 2004]. On contrary, a strong overexpression of IGF-IR has been described in ACCs, but not in ACAs [Fottner et al. 2004]. These elevated levels of IGF-IR in combination with a high concentration of IGF-II may be representing an autocrine stimulatory loop by which it contributes to adrenocortical tumorigenesis [Fottner et al. 2004].
As mentioned before, it seems that IGF-IIR clears and inactivates IGF-II, thereby playing an important role in regulating cell growth. In human ACCs there is a frequent loss of heterozygosity (LOH) at the IGF-IIR locus. This may contribute to an increased IGF-II bioavailability. In ACAs LOH was detected in only 9%, compared to 58% in ACCs, which suggests that the changes in the IGF-IIR gene locus are a late step in adrenocortical tumorigenesis [Fottner et al. 2004]. 












Before all the sections were stained, the protocols for immunohistochemical staining were optimised for the different antibodies. The optimised protocols were as follows:

Insulin-like growth factor I receptor (IGF-IR)
Immunohistochemical staining was performed on paraffin-embedded adrenal tissue sections. The sections were deparaffinized in xylene (2x5 min) and in a descending serie of ethanol they were rehydrated (3 min 96%, 3 min 80%, 2 min 70%, 2 min 60%). The sections were washed in a 10% tris buffered saline solution (TBS), with pH 7,6 (2x5 min), and subsequently in TBS + 0,025% Triton X-100 (TBST) (2x5 min). A treatment with 10% normal goat serum in 1% bovine serum albumine (BSA) in TBST was performed to block non-specific antibody binding (30 min). The sections were incubated overnight at 4 ºC with a rabbit polyclonal IGF-IR antibody (PAB18560 Abnova), diluted 1:200 in 1% BSA in TBST. Following a wash step in TBST (2x5 min), incubation with 0,35% H2O2 in TBS took place to block endogenous peroxidase (15 min). Again, the slides were washed in TBST (2x5 min). And then they were incubated with evision anti-rabbit HRP (Dako, Carpinteria, CA, USA), the second anitbody (30 min). After washing with TBS (2x5 min), the sections were incubated with DAB-solution (Dako) for 3 minutes and then washed in Milli-Q (5 min). Hematoxylin was applied for 5 seconds to counterstain, followed by washing in tapwater (10 min). After dehydration by an ascending ethanol serie (2 min 60%, 2 min 70%, 3 min 80%, 2x3 min 96%) an xylene (2x5 min), the slides were mounted with Vectamount-permanent mounting medium. 

Insulin-like growth factor II receptor (IGF-IIR)
The same method as for IGF-IR, was used for immunohistochemistry for IGF-IIR. The only difference was the duration of incubation with DAB-solution (Dako), which was 2 minutes with IGF-IIR. The antibody used was a polyclonal rabbit IGF-IIR antibody (PAB18393 Abnova), diluted 1:200 in 1% BSA in TBST. 

Growth hormone receptor (GHR)
Again, the same method as previously described was used for the immunohistochemical staining. The incubation with DAB-solution was 10 minutes. A mouse monoclonal anti-GHR antibody (ab11380 Abcam) was used as the primary antibody. The secondary antibody used was envision anti-mouse (Dako). 

Growth hormone (GH)
As the primary antibody a rabbit polyclonal anti-GH antibody (7801H) was used, with envision anti-rabbit (Dako) as the second antibody. The sections were incubated with DAB-solution for 3 minutes. The method for staining was equal to those previously described. 

3.3 Scoring method of immunohistochemistry

The sections were assessed on the location of the staining in the cells, the proportion of positive stained cells and the intensity of staining. For the normal adrenal tissues, the glomerulosa and fasciculata were separately assessed. 
The staining could be located in the cytoplasm, the cell membrane, the nucleus and/or the nuclear membrane. The gradation used for the proportion of positive cells throughout the slide was in the range of 0-4; no staining ,0; 1-25% cells positive, 1; 26-50% cells positive, 2; 51-75% cells positive, 3; 76-100% cells positive, 4. These numbers were replaced by the class middle (1  12,5%, 2  37,5%, 3  62,5%, 4  87,5%) for the statistical analyses. 
Only adrenal cells were taken into account, all other cells (like connective tissue and endothelium) were left outside. The intensity of staining was graded 0-3; negative, 0; weak, 1; moderate, 2; strong, 3. This was based on the mean intensity when there was heterogeneous staining. 



























4.1 Location of staining

The IHC demonstrated the following location of the GH, GHR, IGF-IR and IGF-IIR in the normal adrenal glands and ATs (table 1). 








4.2 Proportion and intensity of staining

The IHC staining of the GHR demonstrated significantly intenser staining in the ACAs when compared to normal adrenal glands (table 7). The proportion of staining of staining with antibodies against GHR and the proportion and the intensity of staining with antibodies against GH, IGF-IR and IGH-IIR between ACA, ACC and normal adrenals, did not differ significantly (tables 6, 8-13). 

Table 2: Proportion and intensity of staining - GH





Normal adrenal: zona glomerulosa	Intensity	7	1,81	,49	1,00	1,288
	Proportion	7	17,07	11,50	,00	30,42
Normal adrenal: zona fasciculata	Intensity	7	1,48	,29	1,00	,77
	Proportion	7	6,55	3,26	,00	8,62





Table 3: Proportion and intensity of staining – GHR





Normal adrenal: zona glomerulosa	Intensity	7	2,10	,16	2,00	,42
	Proportion	7	57,73	9,55	62,50	25,28




Table 4: Proportion and intensity of staining – IGF-IR





Normal adrenal: zona glomerulosa	Intensity	7	3,72	,18	4,00	,49
	Proportion	7	80,36	7,14	87,50	18,90




Table 5: Proportion and intensity of staining – IGF-IIR





Normal adrenal: zona glomerulosa	Intensity	7	3,09	,38	3,33	,99
	Proportion	7	57,74	11,62	62,50	30,75






Table 6: ANOVA analysis of GH - Intensity of staining 









Group 1 = ACCs, group 2 = ACAs, group 3 = normal adrenal glands


Table 7: ANOVA analysis of GHR – Intensity of staining









Group 1 = ACCs, group 2 = ACAs, group 3 = normal adrenal glands	
*. The mean difference is significant at the 0.05 level.


Table 8: ANOVA analysis of IGF-IR - Intensity of staining












Table 9: ANOVA analysis of IGF-IIR - Intensity of staining








Group 1 = ACCs, group 2 = ACAs, group 3 = normal adrenal glands


Table 10: ANOVA analysis of GH – Proportion of staining








Group 1 = ACCs, group 2 = ACAs, group 3 = normal adrenal glands


Table 11: ANOVA analysis of GHR - Proportion of staining













Table 12: ANOVA analysis of IGF-IR - Proportion of staining








Group 1 = ACCs, group 2 = ACAs, group 3 = normal adrenal glands


Table 13: ANOVA analysis of IGF-IIR - Proportion of staining













A significant higher intensity of the staining of GHR was demonstrated in the ACAs as compared to the normal adrenal glands. In addition, the intensity of staining in ACAs is also higher than in the ACCs (although this is not significant). The proportion of staining was not significantly different. These results make the role of GHR in tumorigenesis less likely. 
There were no significant differences between the intensity or proportion of staining of GH, IGF-IR and IGF-IIR between the normal adrenal glands and the ATs. Therefore, there also seems to be no roles for GH, IGF-IR and IGF-IIR in tumorigenesis in adrenal tissue. 
Based on these results, the use of GH-inhibitors or the use of GHR-, IGF-IR-, or IGF-IIR-blockers do not seem useful in the treatment of dogs with cortisol-producing adrenocortical tumors. 
Unfortunately, there were some shortcomings in this research. The most important one being the immunohistochemical staining protocol, which may not have been specific enough. The staining was very different among the sections in one group. Further optimising of the protocols may be needed.
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